TL;DR
Turn quiet afternoons into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
A Nov. 5 gastroenterology research roundup highlighted estimates that gallbladder and biliary diseases affected more than 264 million people and contributed to over 146,000 deaths worldwide in 2023. It also summarized a study examining whether symptom profiles predict response to low-dose amitriptyline for IBS and research linking rectal location of large polyps with greater odds of invasive cancer and recurrence after removal.
A Nov. 5 gastroenterology research roundup reported that gallbladder and biliary diseases affected more than 264 million people worldwide in 2023 and contributed to over 146,000 deaths. The MedPage Today report also highlighted research on whether symptom patterns predict response to low-dose amitriptyline for irritable bowel syndrome (IBS), and a study associating rectal location of large polyps with higher odds of invasive cancer and recurrence after endoscopic removal.
The global disease estimates, cited by MedPage Today from The Lancet Gastroenterology & Hepatology, cover conditions including gallstones, gallbladder inflammation and cholangitis. The roundup did not provide country-level figures, the methods used to calculate the totals or a comparison with earlier years, so the reported numbers describe the scale in 2023 but do not establish a trend.
For IBS, the roundup pointed to a study in Clinical Gastroenterology and Hepatology asking whether gastrointestinal and psychological symptom profiles can predict response to low-dose amitriptyline. The source summary states the research question but gives no results, participant count or effect estimates. It therefore does not establish which patients may benefit or how large any difference in response might be.
A retrospective cohort study from Poland, published in Gut, found that among patients who underwent endoscopic mucosal resection for large colorectal polyps, rectal lesions were linked to greater likelihood of invasive cancer and recurrence than lesions in the colon. The roundup did not supply the size of the increased risks or details about follow-up. Its wording describes an association, not proof that a polyp’s location caused either outcome.
Three Findings With Different Clinical Stakes
The figures on biliary disease put a large worldwide health burden in view: the reported 264 million cases and more than 146,000 deaths in 2023 span several distinct conditions. Without regional breakdowns or a year-to-year comparison, however, the numbers cannot show where the burden is greatest or whether it is rising.
The IBS work addresses a practical question for clinicians and patients: whether symptoms might help anticipate response to an existing medicine. But the roundup provides only the study’s research question, not its findings, so it cannot support a treatment choice. The rectal-polyp study, meanwhile, suggests that lesion location may be relevant when clinicians assess outcomes after removal; the reported association alone does not prescribe a different surveillance plan.
Products Worth Considering
Fitbit Versa 2 Health and Fitness Smartwatch with Heart Rate, Alexa, Music, Sleep and Swim Tracking
Fitbit Inspire 3 Health and Fitness Tracker Bundle
Coway Mighty AP-1512HH(W) Air Purifier, White
As an affiliate, we earn on qualifying purchases.
The Research Behind the Roundup
The source is a short gastroenterology and hepatology research roundup by Ian Ingram, MedPage Today’s managing editor, published Nov. 5, 2026. It assembled findings from several journals rather than reporting one new trial or a single coordinated study. Its topics included biliary disease estimates, an IBS research question and a retrospective analysis of large colorectal polyps.
The roundup also listed unrelated developments, including a case study of gene correction for severe alpha-1 antitrypsin deficiency, consensus definitions for acute-on-chronic liver failure and an inspector general report on hepatitis C treatment among Medicaid beneficiaries. Those items were not presented as part of the three findings covered here and do not provide additional evidence about the IBS or polyp studies.
“Can certain gastrointestinal and psychological symptom profiles in irritable bowel syndrome predict response to low-dose amitriptyline?”
— MedPage Today, summarizing the Clinical Gastroenterology and Hepatology study
Study Results and Risk Estimates Missing
The roundup does not give the methods or regional breakdown behind the global biliary estimates, or explain how the total compares with previous years. It also omits the IBS study’s results, sample size and treatment-response measures. Readers cannot tell from this summary whether symptom profiles meaningfully predicted response.
For the Polish polyp study, the summary provides no numerical risk estimates, confidence intervals, participant count or follow-up duration. The retrospective design can identify associations but cannot by itself establish cause and effect. It is also unclear from the report whether the findings should change clinical follow-up; no such recommendation is included.
Full Studies Will Add Detail
The next step for readers seeking more than the roundup is to consult the cited journal papers: The Lancet Gastroenterology & Hepatology for the 2023 disease estimates, Clinical Gastroenterology and Hepatology for the IBS analysis and Gut for the polyp cohort study. Those papers are needed to assess study methods, populations, effect sizes and limitations.
The source does not announce a follow-up date, additional results or a policy change arising from these findings. Until fuller details are available, the biliary figures should be treated as estimates for 2023, the IBS item as a question under study, and the rectal-polyp finding as an observed association rather than a confirmed cause.
Key Questions
How many people had gallbladder or biliary disease in 2023?
The roundup cited an estimate of more than 264 million people worldwide with gallbladder and biliary diseases in 2023. The conditions included gallstones, cholecystitis and cholangitis.
Did the IBS study show that amitriptyline works?
The roundup does not report the study’s results. It says researchers examined whether gastrointestinal and psychological symptom profiles could predict response to low-dose amitriptyline; it does not establish effectiveness or identify who may respond.
What did the study find about large rectal polyps?
A retrospective Polish cohort study associated rectal location with a higher likelihood of invasive cancer and recurrence than colonic location among patients whose large polyps were removed by endoscopic mucosal resection. The summary gives no numerical risk estimates.
Do the polyp findings prove rectal location causes worse outcomes?
No. The report describes an association in a retrospective study. The roundup does not establish cause and effect or say whether the findings call for changes to follow-up care.
Source: medpagetoday.com
